主题：【分享】印度传统医学关于预防和控制新型冠状病毒的建议

    新型冠状病毒在全球持续蔓延，目前仍未有特别有效的治疗药物。还盼医药研究者继续努力早日找到有效的治疗方法。对于新型冠状病毒的预防和干预，印度传统医学也根据自己的研究给出了相关建议，以下为该建议（的主要内容），供国内学者参考。 
      印度政府已采取多项措施，利用印度传统医学系统的潜力来遏制新型冠状病毒（COVID-19）流行病的影响。印度传统医学司发布了各种指导方针和建议，以提高免疫力，并建议普通公众容易获得的简单家庭治疗措施。在2021年4月新型冠状病毒再次爆发期间，印度传统医学司还发布了印度传统医学从医者对新型冠状病毒患者居家隔离的指导方针。印度传统医学司与一些研究机构如ICMR、CSIR、DBT、AIMS（新德里、佐德普尔、贾贾尔）、勒克瑙国王乔治医科大学、BHU医学科学研究所、那格浦尔政府医学院等合作，为使用印度传统医学预防和控制新型冠状病毒提供了大量证据。总的来说，卫生部下属的研究委员会和国家研究所根据印度传统医学司成立的跨学科印度传统医学研发工作组的建议，开展了139项临床、临床前和流行病学研究。它包括44项预防性、44项独立和附加治疗、15项观察性和10项调查性研究以及22项实验性研究、两项药典标准制定和两项系统评价。以下建议是基于证据的，是印度传统医学司为预防和控制新型冠状病毒而开展的研发成果（具体药物成分见编者注）：


*这些干预措施包含在印度传统医学司所颁布的“基于阿育吠陀和瑜伽医学的新型冠状病毒治疗的国家临床管理规程”和“各印度传统医学从业者对新型冠状病毒患者居家隔离指南”中。

其他印度传统医学对于新型冠状病毒的预防干预方法



免责声明：上表中提到的印度传统医学干预措施应在注册印度传统医学从业者的监督下进行。

参考文献

1. Reddy RG, Gosavi RV, Yadav B et al. AYUSH-64 as an add-on to standard care in asymptomatic and mild cases of COVID-19: A randomized controlled trial. AYU 2020; 41:107-16.

2. Chopra A, Chavan-Gautam P, Tillu G, et al. Co-administration of AYUSH 64 as an adjunct to Standard of Care in mild and moderate COVID-19: A randomised, controlled, multicentric clinical trial. Preprint available at: https://www.medrxiv.org/content/10.1101/2021.06.12.21258345v1

3. Thakar A, Goyal M, Bhinde S, Chhotala Y, Panara K, Chaudhari S. Efficacy of AYUSH-64 as add-on therapy in early stage COVID-19 —An open-label randomized controlled pilot study. 2021. Preprint available at: https://doi.org/10.31219/osf.io/t8wza

4. Singh H, Srivastava S, Yadav B, et al. AYUSH-64 as an adjunct to Standard Care in mild to moderate COVID-19: An open-label randomized controlled trial in Chandigarh, India. Preprint available at: https://osf.io/xyuas/

5. Singh NR, Madan A, Yadav B, et al. Effect of an Ayurvedic intervention (Ayush-64) in mild to moderate COVID-19: An exploratory prospective single arm clinical trial. Preprint available at: https://osf.io/azb9t/

6. Shamkumar M, Rajput S, Yadav B, et al. Ayurveda formulation AYUSH 64 in asymptomatic and mild COVID 19 infection-A prospective, open label Clinical Study. Preprint available at: https://osf.io/6xa9u/

7. Srivastava A, Rengaraju M, Srivastava S, et al. Efficacy of Two Siddha Polyherbal Decoctions, Nilavembu Kudineer and KabaSura Kudineer, along with Standard Allopathy Treatment in the Management of Mild to Moderate Symptomatic COVID-19 Patients – a Double-Blind, Placebo Controlled, Clinical Trial. Trials. 2021 Aug 28;22(1):570. doi: 10.1186/s13063-021-05478-0.

8. Natarajan S, Anbarasi C, Sathiyarajeswaran P, et al. Kabasura Kudineer (KSK), a poly-herbal Siddha medicine, reduced SARS-CoV-2 viral load in asymptomatic COVID-19 individuals as compared to vitamin C and zinc supplementation: findings from a prospective, exploratory, open-labeled, comparative, randomized controlled trial, Tamil Nadu, India. Trials. 2021 Sep 15;22(1):623. doi: 10.1186/s13063-021-05583-0. 9. Chopra A, Srikanth N, Patwardhan B; AYUSH CCRAS Research Group. Withania somnifera as a safer option to hydroxychloroquine in the chemoprophylaxis of COVID-19: Results of interim analysis. Complement Ther Med. 2021;62:102768. doi:10.1016/j.ctim.2021.102768

10. A safer option to hydroxychloroquine in the chemoprophylaxis of COVID-19 in high-risk health- care workers: A randomized controlled, non-inferiority trial. Preprint available at: https://osf.io/s3v6k/

11. An Open label prospective interventional study to assess the prophylactic effect of GuduchiGhanVati in COVID-19: A community-based study in a containment zone of Himachal Pradesh, India. doi: 10.31219/osf.io/8vwsy. Preprint available at: https://osf.io/8vwsy

12. GuduchiGhanavati to Improve Immune Status and General Health in the Population at High Risk of COVID-19: Results of An Open-Label Non-Randomized Clinical Trial from India. Preprint available at: https://europepmc.org/article/ppr/ppr296363

13. Godatwar PK, Deshpande S, JoshiDeshmukh PS, et al. Clinical evaluation of Chyawanprash as a preventive measure during the COVID-19 pandemic: An open-label, multicentric, randomized, comparative, prospective, and interventional community-based clinical study on healthy individuals. J Indian Sys Medicine 2021;9:104-13.

14. Jindal N, Rajput S, Yadav B, et al. Chyawanprash as add on to the standard of care in preventing COVID19 infection among apparently healthy health care workers – A single arm, longitudinal study. Ann Ayurvedic Med. 2021; 10(3) 204-219. doi: 10.5455/AAM.73639

15. Rizvi ZA, Tripathy MR, Sharma N, et al. Effect of Prophylactic Use of Intranasal Oil Formulations in the Hamster Model of COVID-19. Front. Pharmacol. 2021 12:746729. doi: 10.3389/fphar.2021.746729

16. Khan F, Ali S, Ganie BA, Rubab I. Immunopotentiating effect of Khamira Marwarid, an herbo-mineral preparation. Methods Find Exp Clin Pharmacol. 2009 Oct; 31(8):513-22. doi: 10.1358/mf.2009.31.8.1419719.

17. Effectiveness of Arsenic Album 30C in prevention of Covid 19 in Individuals residing in Containment Zones of Delhi-A prospective Community Based Cohort Study. Accepted for publication in Journal 'Homeopathy' (Ref No. HOMP-D-21-00070R3)

编者注：



说明：有些药物没有找到相应的中文名，采用印度名称并在括号中注出拉丁学名/解释说明的方式。

本文仅供学习交流，所有知识产权及解释均归印度相关方面。